EA201690006A1 - Сухая порошковая композиция, содержащая антихолинергический агент, кортикостероид и бета-адренергический агент, для введения путем ингаляции - Google Patents

Сухая порошковая композиция, содержащая антихолинергический агент, кортикостероид и бета-адренергический агент, для введения путем ингаляции

Info

Publication number
EA201690006A1
EA201690006A1 EA201690006A EA201690006A EA201690006A1 EA 201690006 A1 EA201690006 A1 EA 201690006A1 EA 201690006 A EA201690006 A EA 201690006A EA 201690006 A EA201690006 A EA 201690006A EA 201690006 A1 EA201690006 A1 EA 201690006A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agent
dry powder
corticosteroids
inhalation
introduction
Prior art date
Application number
EA201690006A
Other languages
English (en)
Other versions
EA029125B1 (ru
Inventor
Росселла Муза
Ирене Паскуали
Ацита Аскей-Сарвар
Франческа Скьяретти
Original Assignee
Кьези Фармасьютичи С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51292914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201690006(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Кьези Фармасьютичи С.П.А. filed Critical Кьези Фармасьютичи С.П.А.
Publication of EA201690006A1 publication Critical patent/EA201690006A1/ru
Publication of EA029125B1 publication Critical patent/EA029125B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к сухим порошковым композициям для ингаляции, содержащим комбинацию антихолинергического агента, агониста бета-адренорецепторов длительного действия и кортикостероида, способу их приготовления и их терапевтическим применениям.
EA201690006A 2013-07-11 2014-07-10 Сухая порошковая композиция, содержащая антихолинергический агент, кортикостероид и бета-адренергический агент, для введения путем ингаляции EA029125B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13176114 2013-07-11
EP13194763 2013-11-28
PCT/EP2014/064824 WO2015004243A1 (en) 2013-07-11 2014-07-10 Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation

Publications (2)

Publication Number Publication Date
EA201690006A1 true EA201690006A1 (ru) 2016-07-29
EA029125B1 EA029125B1 (ru) 2018-02-28

Family

ID=51292914

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690006A EA029125B1 (ru) 2013-07-11 2014-07-10 Сухая порошковая композиция, содержащая антихолинергический агент, кортикостероид и бета-адренергический агент, для введения путем ингаляции

Country Status (34)

Country Link
US (2) US9402825B2 (ru)
EP (3) EP3569222B1 (ru)
JP (1) JP6426167B2 (ru)
KR (2) KR102275904B1 (ru)
CN (1) CN105338960B (ru)
AU (1) AU2014289185B2 (ru)
BR (1) BR112015030914B1 (ru)
CA (1) CA2917752C (ru)
CL (1) CL2016000028A1 (ru)
CY (2) CY1120806T1 (ru)
DK (2) DK3019153T3 (ru)
EA (1) EA029125B1 (ru)
ES (2) ES2867552T3 (ru)
GE (1) GEP20186853B (ru)
HK (1) HK1218712A1 (ru)
HR (2) HRP20182008T1 (ru)
HU (2) HUE053957T2 (ru)
IL (1) IL243507A0 (ru)
LT (2) LT3409270T (ru)
MX (1) MX2016000290A (ru)
MY (1) MY176176A (ru)
NZ (1) NZ715797A (ru)
PE (2) PE20160372A1 (ru)
PH (1) PH12016500043B1 (ru)
PL (2) PL3409270T3 (ru)
PT (1) PT3019153T (ru)
RS (2) RS57799B1 (ru)
SA (1) SA516370373B1 (ru)
SG (1) SG11201600110RA (ru)
SI (2) SI3409270T1 (ru)
TN (1) TN2016000007A1 (ru)
TW (1) TWI642450B (ru)
UA (1) UA116907C2 (ru)
WO (1) WO2015004243A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113832C2 (xx) * 2009-12-23 2017-03-27 Комбінаційна терапія для хозл
ES2938466T3 (es) * 2012-01-25 2023-04-11 Chiesi Farm Spa Formulación en polvo seco que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación
UA116907C2 (uk) * 2013-07-11 2018-05-25 К'Єзі Фармачеутічі С.П.А. Композиція у вигляді сухого порошку, яка містить антихолінергічний, кортикостероїдний та бета-адренергічний засіб, для інгаляцій
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
TR201407010A2 (tr) 2014-06-16 2015-12-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Vilanterol formülasyonları.
JP6600961B2 (ja) * 2015-03-30 2019-11-06 ブラザー工業株式会社 表示制御装置、表示制御方法及び記憶媒体
BR112017023351B1 (pt) * 2015-05-01 2023-11-28 Board Of Regents, The University Of Texas System Composição farmacêutica e uso da composição farmacêutica
HUE049751T2 (hu) 2015-11-16 2020-10-28 Chiesi Farm Spa Eljárás antikolinerg szert, kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény elõállítására
PE20181377A1 (es) * 2015-11-16 2018-09-05 Chiesi Farm Spa Proceso para preparar una formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico
BR112019009594A2 (pt) * 2016-11-10 2019-10-22 Medisca Pharmaceutique Inc processos e sistemas de composição farmacêutica
MX2019012930A (es) * 2017-05-11 2020-01-14 Chiesi Farm Spa Proceso para preparacion de una formulacion de polvo seco que incluye un anticolinergico, un corticosteroide y un beta-adrenergico.
RU2742376C1 (ru) * 2017-05-11 2021-02-05 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
BR112022004970A2 (pt) 2019-09-24 2022-08-23 Chiesi Farm Spa Formulação de pó seco, processo para preparar uma formulação de pó seco e inalador de pó seco

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1131059B1 (de) * 1998-11-13 2003-03-05 Jago Research Ag Trockenpulver zur inhalation
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
JP5698423B2 (ja) * 2000-06-27 2015-04-08 ベクトゥラ・リミテッド 医薬組成物で使用するための粒子の製造法
PT2283817T (pt) * 2000-11-30 2016-08-22 Vectura Ltd Método de fabrico de partículas para utilização numa composição farmacêutica
EP1386630B1 (en) 2002-07-31 2006-05-17 CHIESI FARMACEUTICI S.p.A. Powder inhaler
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
UA113832C2 (xx) 2009-12-23 2017-03-27 Комбінаційна терапія для хозл
EP2515853B1 (en) 2009-12-23 2014-03-19 Chiesi Farmaceutici S.p.A. Combination therapy for COPD
TR201000681A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.
EP2762133A1 (en) * 2010-04-01 2014-08-06 CHIESI FARMACEUTICI S.p.A. Process for preparing carrier particles for dry powders for inhalation
NO2560611T3 (ru) 2010-04-21 2018-06-02
BR112012032330A2 (pt) * 2010-06-22 2016-11-08 Chiesi Farma Spa formulação em pó seco inalável, uso de uma formulação em pó seco, inalador de pó seco e embalagem
ES2938466T3 (es) 2012-01-25 2023-04-11 Chiesi Farm Spa Formulación en polvo seco que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
UA116907C2 (uk) * 2013-07-11 2018-05-25 К'Єзі Фармачеутічі С.П.А. Композиція у вигляді сухого порошку, яка містить антихолінергічний, кортикостероїдний та бета-адренергічний засіб, для інгаляцій

Also Published As

Publication number Publication date
CN105338960A (zh) 2016-02-17
PE20160372A1 (es) 2016-05-19
MX2016000290A (es) 2016-04-13
CA2917752A1 (en) 2015-01-15
UA116907C2 (uk) 2018-05-25
WO2015004243A1 (en) 2015-01-15
CY1120806T1 (el) 2019-12-11
AU2014289185A1 (en) 2016-02-04
BR112015030914A2 (ru) 2017-07-25
US9402825B2 (en) 2016-08-02
HK1218712A1 (zh) 2017-03-10
AU2014289185B2 (en) 2019-05-23
EP3569222B1 (en) 2024-06-26
JP2016523950A (ja) 2016-08-12
PE20212110A1 (es) 2021-11-04
LT3019153T (lt) 2018-11-26
KR102275904B1 (ko) 2021-07-13
RS57799B1 (sr) 2018-12-31
HRP20210704T1 (hr) 2021-06-11
ES2699986T3 (es) 2019-02-13
EP3409270B1 (en) 2021-02-24
TWI642450B (zh) 2018-12-01
KR20160029797A (ko) 2016-03-15
CN105338960B (zh) 2019-06-04
EP3019153B1 (en) 2018-09-05
BR112015030914B1 (pt) 2023-04-04
DK3409270T3 (da) 2021-04-26
SI3019153T1 (sl) 2018-12-31
HUE039827T2 (hu) 2019-02-28
HRP20182008T1 (hr) 2019-01-25
SG11201600110RA (en) 2016-02-26
EP3569222A1 (en) 2019-11-20
KR20210075217A (ko) 2021-06-22
LT3409270T (lt) 2021-07-26
EA029125B1 (ru) 2018-02-28
CL2016000028A1 (es) 2016-08-05
US20150017248A1 (en) 2015-01-15
NZ715797A (en) 2020-06-26
PH12016500043A1 (en) 2016-03-28
HUE053957T2 (hu) 2021-08-30
SI3409270T1 (sl) 2021-07-30
TN2016000007A1 (en) 2017-07-05
EP3019153A1 (en) 2016-05-18
RS61652B1 (sr) 2021-04-29
JP6426167B2 (ja) 2018-11-21
US20160263027A1 (en) 2016-09-15
IL243507A0 (en) 2016-02-29
PL3019153T3 (pl) 2019-02-28
US9808422B2 (en) 2017-11-07
CY1123937T1 (el) 2022-05-27
MY176176A (en) 2020-07-24
SA516370373B1 (ar) 2017-10-11
DK3019153T3 (en) 2018-11-19
TW201536352A (zh) 2015-10-01
EP3409270A1 (en) 2018-12-05
ES2867552T3 (es) 2021-10-20
PH12016500043B1 (en) 2016-03-28
PL3409270T3 (pl) 2021-08-09
PT3019153T (pt) 2018-12-04
GEP20186853B (en) 2018-05-25
CA2917752C (en) 2022-05-03

Similar Documents

Publication Publication Date Title
EA201690006A1 (ru) Сухая порошковая композиция, содержащая антихолинергический агент, кортикостероид и бета-адренергический агент, для введения путем ингаляции
EA201890966A1 (ru) Способ получения сухой порошковой композиции, содержащей антихолинергическое средство, кортикостероид и бета-адренергическое средство
SI2958913T1 (sl) Sfingozin-1-fosfat receptor agonisti, postopki za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo kot aktivno sredstvo
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201890967A1 (ru) Способ получения сухой порошковой композиции, содержащей антихолинергическое средство, кортикостероид и бета-адренергическое средство
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201590887A1 (ru) Композиция
EA201690187A1 (ru) Композиция в форме сухого порошка, содержащая кортикостероид и бета-адренергическое лекарственное средство, для введения ингаляцией
MX2015008766A (es) Compuestos cbd fluorados, composiciones y usos de los mismos.
PH12018500852B1 (en) Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use
EA201791579A1 (ru) Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2 адренергических рецепторов
DK3041476T3 (da) Corticosteroid, der indeholder oralt disintegrerende tabletsammensætninger til eosinofil øsofagit
DOP2016000007A (es) Pirazolpiridinas sustituidas
PH12016501169A1 (en) Fused imidazolyl derivatives, their preparation and use as medicaments
MX2015008733A (es) Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma.
EA201690294A1 (ru) Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
BR112015031820A2 (pt) composto, composição farmacêutica, intermediário, processo para a preparação de um composto e métodos
MX2015016603A (es) Composiciones de corticosteroides.
PH12015502407B1 (en) Tricylic triazolic compounds as sigma receptors ligans
EA201692428A1 (ru) Способ получения сухих порошкообразных составов
EA201692427A1 (ru) Новый способ получения сухих порошкообразных составов
IN2013MU03123A (ru)
GR1008129B (el) Βελτιωμενο φαρμακευτικο σκευασμα περιεχον εναν ανταγωνιστη της αλδοστερονης και μεθοδος για την παρασκευη αυτου